Anaphylactic reaction to recombinant insulin-like growth factor-I
- PMID: 18556970
- DOI: 10.1515/jpem.2008.21.4.381
Anaphylactic reaction to recombinant insulin-like growth factor-I
Abstract
Mecasermin [rDNA] (Increlex; Tercica, Inc.) is recombinant insulin-like growth factor-I (IGF-I) that has been approved to treat growth failure in children with severe primary IGF-I deficiency. Serious allergic reactions related to Increlex therapy have not been reported. We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical